Telos Capital Management Inc. Has $6.13 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Telos Capital Management Inc. raised its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 1.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 15,073 shares of the pharmaceutical company’s stock after acquiring an additional 237 shares during the quarter. Telos Capital Management Inc.’s holdings in Vertex Pharmaceuticals were worth $6,133,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in VRTX. Venturi Wealth Management LLC grew its position in shares of Vertex Pharmaceuticals by 1.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock valued at $933,000 after purchasing an additional 24 shares during the period. Arthur M. Cohen & Associates LLC grew its stake in Vertex Pharmaceuticals by 3.2% in the fourth quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock valued at $326,000 after purchasing an additional 25 shares in the last quarter. Baystate Wealth Management LLC grew its stake in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 25 shares during the last quarter. Cooper Financial Group raised its holdings in Vertex Pharmaceuticals by 1.0% in the 3rd quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock valued at $1,050,000 after acquiring an additional 29 shares during the period. Finally, Arjuna Capital raised its holdings in Vertex Pharmaceuticals by 0.7% in the 3rd quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock valued at $1,521,000 after acquiring an additional 29 shares during the period. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

VRTX has been the topic of a number of recent research reports. Robert W. Baird lowered Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 target price on the stock. in a research note on Wednesday, January 31st. Royal Bank of Canada lifted their target price on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 6th. StockNews.com upgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Wells Fargo & Company lifted their price objective on shares of Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 6th. Finally, HC Wainwright increased their target price on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the stock a “buy” rating in a research report on Thursday, April 11th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $424.62.

Insider Activity

In other news, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at approximately $31,819,732.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Ourania Tatsis sold 354 shares of the stock in a transaction on Monday, February 26th. The shares were sold at an average price of $425.70, for a total value of $150,697.80. Following the completion of the sale, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at $23,755,762.80. The disclosure for this sale can be found here. In the last three months, insiders have sold 12,381 shares of company stock valued at $5,203,249. 0.20% of the stock is currently owned by insiders.

Vertex Pharmaceuticals Price Performance

Shares of VRTX traded down $1.16 during mid-day trading on Wednesday, reaching $393.01. The company had a trading volume of 415,650 shares, compared to its average volume of 1,242,643. The company’s 50 day simple moving average is $415.28 and its 200 day simple moving average is $396.78. Vertex Pharmaceuticals Incorporated has a 1-year low of $316.43 and a 1-year high of $448.40. The company has a market capitalization of $101.58 billion, a price-to-earnings ratio of 28.30, a P/E/G ratio of 1.87 and a beta of 0.35. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.78 and a current ratio of 3.99.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. The company had revenue of $2.52 billion during the quarter, compared to the consensus estimate of $2.50 billion. During the same period last year, the company earned $3.33 earnings per share. Analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.